• 提示：詳情請下載說明書。

• 產(chǎn)品描述： Madrasin (DDD00107587) is a splicing inhibitor that prevents formation of both splicing intermediates and products in vitro and interferes with one or more early steps in the pathway of spliceosome assembly. Madrasin also can inhibit pre-mRNA splicing in vitro and modify splicing of endogenous pre-mRNA in cells

• 靶點(diǎn)： pre-mRNA splicing;DNA/RNASynthesis

• 體外研究：
  Madrasin (10-30 μM; 4-24 hours; HeLa cells) treatment inhibits the splicing of each of the RIOK3, BRD2, and Hsp40, MCL1, CCNA2, AURKA and p27 pre-mRNAs in both HeLa and HEK293 cells. Madrasin (10-30 μM; 4-24 hours; HeLa and HEK293 cells) treatment shows a dose- and time-dependent inhibitory effect on cell cycle progression. RT-PCR Cell Line: HeLa cells Concentration: 10 μM, 20 μM, or 30 μM Incubation Time: 4 hours, 8 hours, or 24 hours Result: Increased in inhibition of pre-mRNA splicing. Cell Cycle Analysis Cell Line: HeLa and HEK293 cells Concentration: 10 μM, 20 μM, or 30 μM Incubation Time: 4 hours, 8 hours, or 24 hours Result: In the presence of 10 μM 8 hours after treatment, the proportion of cells in G2, M, and S phases increased, with a concomitant decrease in the number of G1 phase cells. This effect increased over time, with >40% of cells in G2 and M phase and >50% in S phase 24 hours.

• 參考文獻(xiàn)：
  1. Andrea Pawellek et al. Identification of Small Molecule Inhibitors of Pre-mRNA Splicing. J Biol Chem, 2014 Dec 12, 289(50): 34683-34698.

• 溶解性： Soluble  in  DMSO

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	3.212 ml	16.06 ml	32.119 ml
  5 mM	0.642 ml	3.212 ml	6.424 ml
  10 mM	0.321 ml	1.606 ml	3.212 ml
  50 mM	0.064 ml	0.321 ml	0.642 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號：

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *